Celldex Therapeutics (CLDX)

P/S ratio as of November 2026 (TTM): > 1000

According to Celldex Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.47. At the end of 2023 the company had a P/S ratio of 315.

P/S ratio history for Celldex Therapeutics from 2001 to 2023

PS ratio at the end of each year

Year	P/S ratio	Change
2023	315	-64.62%
2022	891	129.46%
2021	388	314.91%
2020	93.5	783.15%
2019	10.6	184.57%
2018	3.72	-87.72%
2017	30.3	-42.63%
2016	52.8	-81.29%
2015	282	-38.08%
2014	456	-13.25%
2013	526	1263.33%
2012	38.6	211.18%
2011	12.4	338.95%
2010	2.82	-71.05%
2009	9.75	-41.89%
2008	16.8	23.99%
2007	13.5	-33.39%
2006	20.3	-55.02%
2005	45.1	107.81%
2004	21.7	-43.23%
2003	38.3	274.72%
2002	10.2	-85.9%
2001	72.4

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Pfizer PFE	2.64	-99.98%	🇺🇸 USA
Amgen AMGN	6.59	-99.96%	🇺🇸 USA
GSK plc GSK	2.31	-99.99%	🇬🇧 UK
Titan Pharmaceuticals TTNP	N/A	N/A	🇺🇸 USA
Seagen SGEN	18.8	-99.88%	🇺🇸 USA
Agenus AGEN	2.56	-99.98%	🇺🇸 USA
Emergent BioSolutions EBS	0.4305	-100.00%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Celldex Therapeutics (CLDX)

P/S ratio as of November 2026 (TTM): > 1000